Stent Test Suggests Not Much Difference Between Rivals

Updated from 8:01 a.m. EST

The coronary stent showdown looks like a draw.

Results from the Reality trial, released today at the American College of Cardiology annual conference in Orlando, Fla., suggest that both Johnson & Johnson's(JNJ Quote) Cypher and Boston Scientific's(BSX Quote) Taxus drug-coated stents were comparable in preventing artery reclogging.

The study said that both products were "efficacious, at comparable rates, in preventing in-segment binary restenosis (re-clogging), which was the primary endpoint of the study, in moderately complex patients." ...